ProCE Banner Activity

CE / CME

My Take on Key Studies in CAR T-Cell Therapy From ASH 2019

Clinical Thought
CAR T-cell therapy was one of the hottest topics at the 2019 ASH annual meeting. In this commentary, Michael R. Bishop, MD, provides his thoughts on key studies on this topic from the meeting.

Pharmacists: 0.25 contact hour (0.025 CEUs)

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Nurses: 0.25 Nursing contact hour

Released: January 31, 2020

Expiration: January 30, 2021

No longer available for credit.

Share

Faculty

Michael R. Bishop

Michael R. Bishop, MD

Professor of Medicine, Director
Section of Hematology/Oncology,
Cellular Therapy Program
University of Chicago
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Celgene

Gilead

Target Audience

This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with leukemia, lymphoma, and/or myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Integrate axicabtagene ciloleucel and tisagenlecleucel into the individualized clinical management of appropriate patients with leukemia or lymphoma
  • Describe current research on CAR T-cell therapy combinations to combat treatment resistance

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Michael R. Bishop, MD

Professor of Medicine, Director
Section of Hematology/Oncology,
Cellular Therapy Program
University of Chicago
Chicago, Illinois

Michael R. Bishop, MD, has disclosed that he has received honoraria from Agios, Celgene, Gilead Sciences/Kite, OptumHealth, Pharmacyclics, and Sanofi; has served on speaker bureaus for Agios, Celgene, Gilead Sciences/Kite, Pharmacyclics, and Sanofi; and has received consulting fees from CRISPR, Gilead Sciences/Kite, Juno, Novartis, and OptumHealth.

Staff Disclosure

Staff

Jason J. Everly, PharmD

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy Quill, PhD, has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour.

Credit Designation

CCO designates this continuing education activity for 0.25 contact hours (0.025 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-20-021-H01-P

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 100% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 31, 2020, through January 30, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ knowledge of and competence in leveraging CAR T-cell therapies to individualize clinical management of patients with B-cell malignancies: leukemias, lymphomas, and myeloma.